TSHA vs. FATE, EDIT, VYGR, ALLO, ALEC, LXEO, OCGN, CABA, TCRX, and CCCC
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Fate Therapeutics (FATE), Editas Medicine (EDIT), Voyager Therapeutics (VYGR), Allogene Therapeutics (ALLO), Alector (ALEC), Lexeo Therapeutics (LXEO), Ocugen (OCGN), Cabaletta Bio (CABA), TScan Therapeutics (TCRX), and C4 Therapeutics (CCCC). These companies are all part of the "biological products, except diagnostic" industry.
Fate Therapeutics (NASDAQ:FATE) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Taysha Gene Therapies has a net margin of -833.60% compared to Taysha Gene Therapies' net margin of -2,933.79%. Taysha Gene Therapies' return on equity of -46.49% beat Fate Therapeutics' return on equity.
In the previous week, Taysha Gene Therapies had 12 more articles in the media than Fate Therapeutics. MarketBeat recorded 26 mentions for Taysha Gene Therapies and 14 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.27 beat Taysha Gene Therapies' score of 0.11 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.
Taysha Gene Therapies has lower revenue, but higher earnings than Fate Therapeutics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fate Therapeutics received 391 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 73.95% of users gave Taysha Gene Therapies an outperform vote while only 68.62% of users gave Fate Therapeutics an outperform vote.
Fate Therapeutics presently has a consensus target price of $6.58, indicating a potential upside of 69.24%. Taysha Gene Therapies has a consensus target price of $7.00, indicating a potential upside of 125.08%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Fate Therapeutics.
Fate Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by company insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Taysha Gene Therapies beats Fate Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
